【2023ASH抢先看】中国血液之音奏响国际大会，口头发言将破60项！

摘要号879：新诊断多发性骨髓瘤患者中MGUS样特异性转录特征和克隆选择表达谱可预测良好预后

• 原标题：The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

• 发言人：严文强 中国医学科学院血液病医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)

摘要号1093：非预处理化疗或GvHD预防性CD7 CAR-T治疗桥接单倍体造血干细胞移植

• 原标题：Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

• 发言人：Yongxian Hu 浙江大学医学院第一附属医院

• 汇报时间：Monday, December 11, 2023: 4:30 PM-6:00 PM
  

• 汇报地点：Ballroom 20AB (San Diego Convention Center)

摘要号1041：单倍体造血细胞干细胞联合非亲缘性脐带血移植治疗成人急性髓系白血病可较单倍体造血细胞移植提高生存率：一项多中心、随机、III期试验的结果

• 原标题：Haploidentical Hematopoietic Cell Transplantation Combined with an Unrelated Cord Blood Unit for Adult Acute Myeloid Leukemia Results in Improved Survival Compared to Haploidentical Hematopoietic Cell Transplantation: Results of a Multicenter, Randomized, Phase III Trial

• 发言人：Biqi Zhou 苏州大学第一附属医院

• 汇报时间：Monday, December 11, 2023: 4:30 PM-6:00 PM
  

• 汇报地点：Ballroom 20AB (San Diego Convention Center)

摘要号1022：一项I期开放标签单臂研究的最新结果：双靶向BCMA和CD19 Fastcar-T细胞（GC012F）作为符合移植条件的新诊断的高风险多发性骨髓瘤的一线治疗

• 原标题：Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

• 发言人：杜鹃 上海长征医院

• 汇报时间：Monday, December 11, 2023: 4:30 PM-6:00 PM
  

• 汇报地点：Room 6A (San Diego Convention Center)

摘要号1025：C-CAR039——新型抗CD20/CD19双特异性CAR-T细胞疗法在复发/难治性(r/r) B细胞非霍奇金淋巴瘤（B-NHL）患者的长期随访中显示出深度且持久的临床疗效

• 原标题：C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

• 发言人：梁爱斌 同济大学附属同济医院

• 汇报时间：Monday, December 11, 2023: 4:30 PM-6:00 PM
  

• 汇报地点：Room 6A (San Diego Convention Center)

摘要号969：维奈克拉联合柔红霉素和阿糖胞苷（2 + 6）方案治疗急性髓系白血病：一项II期试验的结果更新

• 原标题：Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

• 发言人：Xiaohui Suo 邯郸市中心医院

• 汇报时间：Monday, December 11, 2023: 4:30 PM-6:00 PM
  

• 汇报地点：San Diego Ballroom AB (Marriott Marquis San Diego Marina)

摘要号970：比较维奈克拉联合地西他滨与传统化疗诱导治疗新诊断急性髓系白血病的疗效和安全性——一项多中心随机2b期临床试验的中期分析

• 原标题：Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

• 发言人：Jing Lu 苏州大学第一附属医院

• 汇报时间：Monday, December 11, 2023: 4:30 PM-6:00 PM
  

• 汇报地点：San Diego Ballroom AB (Marriott Marquis San Diego Marina)

摘要号891：达沙替尼联合CAR-T细胞治疗新诊断的成人Ph阳性急性淋巴细胞白血病

• 原标题：Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

• 发言人：Mingming Zhang 浙江大学医学院第一附属医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：Room 6A (San Diego Convention Center)

摘要号889：白细胞介素-6敲低的CD19靶向CAR -T细胞（ssCART-19）治疗复发/难治性B-ALL的疗效和安全性

• 原标题：Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

• 发言人：Lei Yu 上海优卡迪生物医药科技有限公司

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：Room 6A (San Diego Convention Center)

摘要号867：强效BCR-ABL变构抑制剂Tgrx-678在酪氨酸激酶抑制剂（TKI）耐药/难治性慢性髓系白血病（CML）患者中的安全性和有效性：Ⅰ期研究的初步结果

• 原标题：Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

• 发言人：江倩 北京大学人民医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)

摘要号869：在一项注册随机2期研究中，Olverembatinib（HQP1351）对酪氨酸激酶抑制剂（TKI）耐药慢性髓系白血病慢性期（CML-CP）患者的疗效与最佳可用疗法（BAT）的疗效对比

• 原标题：Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

• 发言人：江倩 北京大学人民医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)

摘要号846：克隆进化解剖揭示高MSI2水平促进T细胞性急性淋巴细胞白血病的化疗耐药

• 原标题：Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-Resistance in T-Cell Acute Lymphoblastic Leukemia

• 发言人：章婧嫽 中国医学科学院血液病医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：Grand Hall D (Manchester Grand Hyatt San Diego)

摘要号829：基于外周细胞清除率的伊达比星和阿糖胞苷诱导方案优化：多中心随机3期试验的首个结果（RJ-AML 2016）

• 原标题：Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)

• 发言人：Yunxiang Zhang 上海交通大学医学院附属瑞金医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：San Diego Ballroom AB (Marriott Marquis San Diego Marina)

摘要号834：维奈克拉联合阿扎胞苷、低剂量阿糖胞苷、Aclarubicin和G-CSF（VA-CAG方案）治疗新诊断的年轻急性髓系白血病患者：一项前瞻性、多中心、单组2期临床试验

• 原标题：Venetoclax Plus Azacitidine, Low Dose Cytarabine, Aclarubicin and G-CSF (VA-CAG Regimen) for Newly Diagnosed Young Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase 2 Clinical Trial

• 发言人：Xiaoping Li 中国人民解放军联勤保障部队第九二〇医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：San Diego Ballroom AB (Marriott Marquis San Diego Marina)

摘要号827：Olverembatinib联合维奈克拉低强度化疗治疗新诊断的费城染色体阳性急性淋巴细胞白血病患者:来自II期研究的早期结果

• 原标题：Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study

• 发言人：弓晓媛 中国医学科学院血液病医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM
  

• 汇报地点：Grand Hall C (Manchester Grand Hyatt San Diego)

摘要号761：在Fumanba-1项目中，接受Equecabtagene autoeucel (Eque-cel, CT103A)治疗后实现持续最小残留疾病阴性的多发性骨髓瘤(MM)患者的结局及特征分析

• 原标题：Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

• 发言人：李春蕊 华中科技大学同济医学院附属同济医院

• 汇报时间：Monday, December 11, 2023: 10:30 AM-12:00 PM

• 汇报地点：Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)

摘要号736：奥布替尼联合来那度胺和利妥昔单抗（OLR）治疗中国初治套细胞淋巴瘤（MCL）患者的一项前瞻性、多中心、Il期研究（POLARIS研究）：疗效、安全性、突变谱和突变谱对治疗反应的影响的初步分析结果

• 原标题：A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

• 发言人：张会来 天津医科大学肿瘤医院

• 汇报时间：Monday, December 11, 2023: 10:30 AM-12:00 PM

• 汇报地点：Grand Hall B (Manchester Grand Hyatt San Diego)

摘要号729：儿童和青少年急性髓系白血病患者接受低剂量与标准剂量化疗方案诱导缓解方案治疗(CALSIII-AML18)的结局:一项多中心、3期、随机、非劣效性临床试验

• 原标题：Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial

• 发言人：Gao Li 苏州大学儿童医院

• 汇报时间：Monday, December 11, 2023: 10:30 AM-12:00 PM

• 汇报地点：Room 6A (San Diego Convention Center)

摘要号672：多中心研究的结果显示，HMR突变导致JAK2V617F等位基因负荷较低的骨髓纤维化患者预后不良，而对较高等位基因负荷患者无影响

• 原标题：HMR Mutations Drive Poor Prognosis in Myelofibrosis Patients with Lower JAK2V617F Allele Burden but Not in Those with Higher Allele Burden: Results of a Multicenter Study

• 发言人：Yu-Hung Wang 台北市国立台湾大学医院

• 汇报时间：Sunday, December 10, 2023: 5:45 PM

• 汇报地点：Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)

摘要号621：评估Bomedemstat (MK3543)联合Ruxolitinib治疗骨髓纤维化患者的安全性和有效性的2期研究

• 原标题：Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis

• 发言人：Harinder Gill, MD, MBBS, FRCP, FRCPath 香港大学

• 汇报时间：Saturday, December 9, 2023: 2:00 PM-3:30 PM

• 汇报地点：Ballroom 20AB (San Diego Convention Center

摘要号609：IMM01联合Tislelizumab治疗既往抗PD-1失败的经典霍奇金淋巴瘤：一项评估安全性和初步抗肿瘤活性的开放标签、多中心、2期研究(IMM01-04)

• 原标题：IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity

• 发言人：周可树 郑州大学附属肿瘤医院

• 汇报时间：Sunday, December 10, 2023: 4:30 PM-6:00 PM

• 汇报地点：Grand Hall B (Manchester Grand Hyatt San Diego) 

摘要号524：CD58基因改变及其通过通过LYN/CD22/SHP1轴促进DLBCL中PD-L1和IDO的上调

• 原标题：CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL

• 发言人：徐溪悦 天津医科大学肿瘤医院

• 汇报时间：Sunday, December 10, 2023: 12:15 PM

• 汇报地点：Harbor Ballroom (Manchester Grand Hyatt San Diego)

摘要号471：大剂量地西他滨强化方案比Bu/Cy方案在消除HSCT前可检测到的残留疾病方面更有效：一项多中心前瞻性II期研究

• 原标题：Mega-Dose Decitabine Intensified Regimen Is More Effective at Eliminating Pre-HSCT Measurable Residual Disease Compared to the Bu/Cy Regimen: A Multicenter Prospective Phase II Study

• 发言人：Hao Zheng 北京大学人民医院

• 汇报时间：Sunday, December 10, 2023: 9:30 AM-11:00 AM

• 汇报地点：Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)

摘要号474：改良的MCBC预处理方案提高了难治性/复发性AML的同种异体造血干细胞移植后的无复发生存率

• 原标题：The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

• 发言人：张潇予 中国医学科学院血液病医院

• 汇报时间：Sunday, December 10, 2023: 9:30 AM-11:00 AM

• 汇报地点：Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)

摘要号410：靶向G3BP2通过ELF1-MCL1轴使急性髓系白血病对维奈克拉治疗增敏 

• 原标题：Targeting G3BP2 Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment Via ELF1-MCL1 Axis

• 发言人：Zhixiang Chen 福建医科大学协和医院

• 汇报时间：Sunday, December 10, 2023: 9:30 AM-11:00 AM

• 汇报地点：Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)

摘要号320：IMM01联合阿扎胞苷作为成人高危骨髓增生异常综合征一线治疗的2期研究初步结果

• 原标题：Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

• 发言人：杨威 中国医科大学附属盛京医院 

• 汇报时间：Saturday, December 9, 2023: 4:15 PM

• 汇报地点：Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
  

摘要号304：HH2853治疗复发和/或难治性外周T细胞淋巴瘤的多中心、开放标签、单组Ib期临床试验

• 原标题：A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

• 发言人：林桐榆 四川省肿瘤医院

• 汇报时间：Saturday, December 9, 2023: 4:00 PM-5:30 PM

• 汇报地点：Grand Hall B (Manchester Grand Hyatt San Diego)

摘要号305：Golidocitinib治疗难治性或复发性外周T细胞淋巴瘤：多国关键研究结果的全面分析(JACKPOT8)

• 原标题：Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

• 发言人：宋玉琴 北京大学肿瘤医院

• 汇报时间：Saturday, December 9, 2023: 4:00 PM-5:30 PM

• 汇报地点：Grand Hall B (Manchester Grand Hyatt San Diego) 

摘要号306：林普利赛治疗复发或难治性外周T/NK细胞淋巴瘤的多中心Ⅱ期临床试验

• 原标题：A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

• 发言人：宋玉琴 北京大学肿瘤医院

• 汇报时间：Saturday, December 9, 2023: 5:15 PM

• 汇报地点：Grand Hall B (Manchester Grand Hyatt San Diego)

摘要号289：CD74+白血病相关巨噬细胞在急性髓性白血病中抑制T细胞免疫监视并促进白血病细胞生长

• 原标题：CD74+ Leukemia-Associated Macrophages Supporess T Cell Immune Surveillance and Promote Leukemic Cell Growth in Acute Myeloid Leukemia

• 发言人：Guo Qiu 南方医科大学南方医院

• 汇报时间：Saturday, December 9, 2023: 4:00 PM

• 汇报地点：Room 6CF (San Diego Convention Center)

摘要号239：CD7嵌合抗原受体T细胞治疗与异基因造血干细胞移植桥接显著提高难治性/复发性T细胞急性淋巴细胞白血病/淋巴瘤的长期无病生存率

• 原标题：CD7 Chimeric Antigen Receptor T-Cell Therapy Bridging to Allogeneic Hematopoietic Stem Cell Transplantation Remarkably Improved Long-Term Disease-Free Survival in Refractory/Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma

• 发言人：李智慧 高博博仁医院

• 汇报时间：Saturday, December 9, 2023: 3:00 PM

• 汇报地点：Room 7 (San Diego Convention Center)

摘要号234：短期Blinatumumab作为造血干细胞移植治疗低白血病负荷B细胞急性淋巴细胞白血病的桥接疗法

• 原标题：Short-Term Blinatumomab As a Bridge Therapy for Hematopoietic Stem Cell Transplantation in B-Cell Acute Lymphoblastic Leukemia with Low Leukemia Burden

• 发言人：Hang Zhang 四川大学华西医院

• 汇报时间：Saturday, December 9, 2023: 3:15 PM

• 汇报地点：Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)

摘要号218：自然选择CD7靶向嵌合抗原受体(CAR)-T细胞治疗难治性/复发性急性髓系白血病：I期临床试验

• 原标题：Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

• 发言人：陆佩华 陆道培医院

• 汇报时间：Saturday, December 9, 2023: 2:15 PM

• 汇报地点：Room 6B (San Diego Convention Center）

摘要号188：CSF-Ctdna在中枢神经系统累及的新诊断弥漫性大B细胞淋巴瘤中的临床意义：诊断、治疗和评价的改进

• 原标题：Clinical Implications of CSF-Ctdna in CNS Involvement of Newly Diagnosed Diffuse Large B Cell Lymphoma: An Improvement of Diagnosis, Treatment and Evaluation

• 发言人：Jinhua Liang 南京医科大学第一附属医院

• 汇报时间：Saturday, December 9, 2023: 2:15 PM

• 汇报地点：Grand Hall C (Manchester Grand Hyatt San Diego)

摘要号189：脑脊液和血浆循环游离DNA对新诊断弥漫性大B细胞淋巴瘤的诊断和预后价值

• 原标题：Diagnostic and Prognostic Value of Circulating Cell-Free DNA in Cerebrospinal Fluid and Plasma in Newly Diagnosed Diffuse Large B Cell Lymphoma

• 发言人：李炳宗 苏州大学附属第二医院

• 汇报时间：Saturday, December 9, 2023: 2:30 PM

• 汇报地点：Grand Hall C (Manchester Grand Hyatt San Diego)

摘要号157：口服三氧化二砷/全反式维甲酸/抗坏血酸治疗新诊断的急性早幼粒细胞白血病(APL)：一项正在进行的多中心试验的最新结果

• 原标题：An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial

• 发言人：Harinder Gill, MD, MBBS, FRCP, FRCPath 香港大学

• 汇报时间：Saturday, December 9, 2023: 2:00 PM-3:30 PM

• 汇报地点：Room 6A (San Diego Convention Center)

摘要号123：基于临床数据和数字病理学的骨髓增殖性肿瘤诊断和亚型分化的深度学习模型的开发和验证

• 原标题：Development and Validation of Deep Learning Model for Diagnosis and Subtypes Differentiation of Myeloproliferative Neoplasms Using Clinical Data and Digital Pathology

• 发言人：史仲珣 南京医科大学第一附属医院血液科

• 汇报时间：Saturday, December 9, 2023: 10:00 AM

• 汇报地点： Room 6DE (San Diego Convention Center)

摘要号101：抗BCMA CAR-T细胞治疗后多发性骨髓瘤患者细胞因子释放综合征的单细胞多组学分析

• 原标题：A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

• 发言人：胡永仙 浙江大学医学院第一附属医院

• 汇报时间：Saturday, December 9, 2023: 10:30 AM

• 汇报地点：Room 6DE (San Diego Convention Center)

摘要号83：DDX3X功能丧失可以通过加速NOTCH1 mRNA 翻译从而促进CLL疾病进展

• 原标题：Loss of DDX3X Function Promotes CLL Progression By Facilitating NOTCH1 mRNA Translation

• 发言人：缪祎 江苏省人民医院

• 汇报时间：Saturday, December 9, 2023: 9:30 AM-11:00 AM

• 汇报地点：Grand Hall B (Manchester Grand Hyatt San Diego)

摘要号55：塞利尼索联合维奈克拉和阿扎胞苷治疗新诊断不适合强化疗的急性髓系白血病(AML)：一项多中心、开放标签的前瞻性研究

• 原标题：Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study

• 发言人：Li Yang 上海交通大学医学院附属同仁医院

• 汇报时间：Saturday, December 9, 2023: 9:30 AM

• 汇报地点：Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)

摘要号803：泼尼松加Ivig与泼尼松单药治疗妊娠期免疫性血小板减少症的比较

• 原标题：Prednisone Plus Ivig Compared with Prednisone for Immune Thrombocytopenia during Pregnancy 

• 发言人：Yuxiu Chen 北京大学人民医院

• 汇报时间：Monday, December 11, 2023: 2:45 PM-4:15 PM

• 汇报地点：Room 25 (San Diego Convention Center)

摘要号778：人羊膜上皮干细胞滴眼液治疗眼部慢性移植物抗宿主病的安全性和有效性分析

• 原标题：Safety and Efficacy of Human Amniotic Epithelial Stem Cells Eye Dropin Ocular Chronic Graft-Versus-Host Disease

• 发言人：Xianjing Cheng 陆军医科大学附属新桥医院

• 汇报时间：Monday, December 11, 2023: 10:30 AM-12:00 PM
  

• 汇报地点：Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)

摘要号686：整合素- γ -嘧啶- 8介导的TGF- γ -嘧啶激活参与ITP患者TPO-Ras停药后持续反应的调节

• 原标题：Integrin -Mediated Activation of TGF-α1 Is Involved in Regulating the Sustained Response after TPO-Ras Withdrawal in ITP Patients

• 发言人：Min Xu 华中科技大学同济医学院附属协和医院

• 汇报时间：Monday, December 11, 2023: 10:30 AM-12:00 PM
  

• 汇报地点：Hall A (San Diego Convention Center)

摘要号687：人脐带间充质干细胞治疗免疫性血小板减少症的疗效和安全性分析：一项前瞻性、单中心、单组、I期试验

• 原标题：Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial

• 发言人：徐艳梅 中国医学科学院血液病医院

• 汇报时间：Monday, December 11, 2023: 10:30 AM-12:00 PM
  

• 汇报地点：Hall A (San Diego Convention Center)
  

摘要号688：CD19嵌合抗原受体T细胞治疗免疫性血小板减少症的疗效

• 原标题：The Therapeutic Efficacy of CD19 Chimeric Antigen Receptor T Cells in Immune Thrombocytopenia Model

• 发言人：Yun Wang 山东大学齐鲁医院

• 汇报时间：Monday, December 11, 2023: 10:30 AM-12:00 PM
  

• 汇报地点：Hall A (San Diego Convention Center)

  
  

摘要号857：Srmt (Sintilimab, Rituximab, Methotrexate和Temozolomide)方案治疗新诊断的原发性中枢神经系统淋巴瘤有效性和安全性的II期研究

• 原标题：Comparative Study for Haplo, MSD and MUD Allo-Hcts for Core-Binding Factor AML Patients in CR2: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

• 发言人：曾志勇 福建医科大学第一附属医院

• 汇报时间：Monday, December 11, 2023: 3:45 PM

• 汇报地点：Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

摘要号650：HLA全相合外周血造血干细胞移植后减少移植后环磷酰胺(PTCy)剂量的I/II期研究

• 原标题：Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Identical Peripheral Blood Hematopoietic Stem Cell Transplantation

•  发言人：Hang Zhang 四川大学华西医院

• 汇报时间：Sunday, December 10, 2023: 4:30 PM-6:00 PM

• 汇报地点：Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)

摘要号572：双功能C5抗体/因子H融合蛋白KP104可有效控制血管内和血管外溶血：补体抑制剂初发PNH患者2期研究的中期结果

• 原标题：KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naive PNH Patients

• 发言人：张凤奎 中国医学科学院血液病医院

• 汇报时间：Sunday, December 10, 2023: 4:30 PM-6:00 PM

• 汇报地点：Room 7 (San Diego Convention Center)   

摘要号480：SLC16A7通过调节CD4+ T细胞钙内流和脂质代谢促进aGVHD

• 原标题：SLC16A7 Facilitates aGVHD through Regulating Calcium Influx and Lipid Metabolism of CD4+ T Cells

• 发言人：Xiaoxuan Lai 苏州大学第一附属医院

• 汇报时间：Sunday, December 10, 2023: 9:30 AM-11:00 AM

• 汇报地点：Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)

摘要号476：克隆GZMK+CD8+T细胞被确定为异基因造血干细胞移植后cGVHD诱导的闭塞性毛细支气管炎综合征发病机制的标志

• 原标题：Clonal GZMK+CD8+T Cells Are Identified As a Hallmark of Pathogenesis of cGVHD-Induced Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

• 发言人：Haowen Xiao 浙江大学医学院邵逸夫医院

• 汇报时间：Sunday, December 10, 2023: 9:30 AM-11:00 AM

• 汇报地点：Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)

摘要号366：解读供体端粒长度对同种异体移植结果的影响：端粒长度比年龄更重要

• 原标题：Deciphering the Impact of Donor Telomere Length on Allogeneic Transplantation Outcomes: Telomere Length Matters More Than Age

• 发言人：Hengwei Wu 浙江大学医学院第一附属医院 

• 汇报时间：Saturday, December 9, 2023: 5:15 PM

• 汇报地点： Room 11 (San Diego Convention Center

摘要号286：Ⅰ型血管性血友病遗传多态性对血管性血友病因子水平的影响

• 原标题：The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 Von Willebrand Disease

• 发言人：Yeu-Chin Chen 台北国防医疗中心三科总医院 

• 汇报时间：Saturday, December 9, 2023: 4:45 PM

• 汇报地点：Room 30 (San Diego Convention Center)

摘要号278：GPIb CAAR-T细胞诱导自身反应性B细胞清除治疗免疫性血小板减少症

• 原标题：GPIb CAAR-T Cells Induce Autoreactive B Cells Elimination to Treat Immune Thrombocytopenia

• 发言人：梅恒 华中科技大学同济医学院协和医院

• 汇报时间：Saturday, December 9, 2023: 4:15 PM

• 汇报地点：Saturday, December 9, 2023: 4:00 PM-5:30 PMRoom 33 (San Diego Convention Center)

摘要号279：Iguratimod通过恢复PINK1/Parkin介导的免疫血小板减少症的有丝分裂调节CD4+ T细胞稳态和功能

• 原标题：Iguratimod Regulates CD4+ T-Cell Homeostasis and Function By Restoring PINK1/Parkin-Mediated Mitophagy in Immune Thrombocytopenia

• 发言人：Yuxiu Chen 北京大学人民医院

• 汇报时间：Saturday, December 9, 2023: 4:30 PM

• 汇报地点：Room 33 (San Diego Convention Center)

摘要号281：Notch1调节肝脏血小板生成素的产生

• 原标题：Notch1 Regulates Hepatic Thrombopoietin Production

• 发言人：乔建林 徐州医科大学血液病研究所

• 汇报时间：Saturday, December 9, 2023: 5:00 PM

• 汇报地点：Room 33 (San Diego Convention Center)

摘要号139：线粒体tRNA假尿嘧啶化通过mTOR信号通路调节红细胞生成：对Mlasa和治疗策略的影响

• 原标题：Mitochondrial tRNA Pseudouridylation Regulates Erythropoiesis Via the mTOR Signaling Pathway: Implications for Mlasa and Treatment Strategies

• 发言人：Yajing Chu 中国医学科学院血液病医院

• 汇报时间：Saturday, December 9, 2023: 2:00 PM

• 汇报地点：Room 33 (San Diego Convention Center)
  

摘要号142：ATF4-RPS19BP1轴调节核糖体生物合成促进红细胞生成

• 原标题：The ATF4-RPS19BP1 Axis Modulates Ribosome Biogenesis to Promote Erythropoiesis

• 发言人：郑昭锋 中国医学科学院血液病医院

• 汇报时间：Saturday, December 9, 2023: 2:45 PM

• 汇报地点：Room 33 (San Diego Convention Center)

摘要号10：调节开关调节转录暂停以驱动红细胞生成  

• 原标题：A Mediator Switch Tunes Transcription Pausing to Drive Erythropoiesis

• 发言人：Hsiang-Ying Lee 北京大学生命科学学院

• 汇报时间：Saturday, December 9, 2023: 10:15 AM

• 汇报地点：Room 25 (San Diego Convention Center)

摘要号7：溴结构域蛋白BRD4通过与EHMT1/2相互作用成为终末红细胞生成的转录抑制因子

• 原标题：Bromodomain Protein BRD4 Is a Transcriptional Repressor of Terminal Erythropoiesis By Interacting with EHMT1/2

• 发言人：Meng Zhang 浙江大学附属第一医院

• 汇报时间：Saturday, December 9, 2023: 9:30 AM

• 汇报地点：Room 25 (San Diego Convention Center)

各位大佬～因为小编眼力有限，若有疏漏，欢迎留言补充～谢谢！